AbbVie, a worldwide biopharmaceutical company, recently stated that a representative will present information about Humira (adalimumab) to benefit people who have rheumatologic diseases.
There will be 26 different presentations about Humira. Speakers will spend their time evaluating Humira, its related topics or other investigational treatments for several different autoimmune diseases. The presentations will include real-world evidence designed to heighten the clinical outcomes for people who live with rheumatologic diseases.
The presenters will discuss new data about ABT-494, an investigational medicine. This medicine is a selective JAK1 inhibitor. It is currently involved in phase-three studies to determine its safety and efficacy.
AbbVie states that the data will support the efficacy and safety of the treatment. This success reinforces the company’s dedication to creating novel therapies and treatments for immunology.
Speeches will be given at the Annual European Congress of Rheumatology (EULAR 2016) in London.
"At EULAR 2016, AbbVie is presenting scientific research on adalimumab across autoimmune diseases, including new areas like non-infectious uveitis, where there is an unmet need for patients," Dominik Hochli, vice president, global medical affairs, AbbVie, said. "Building on more than a decade of experience in rheumatology, we are focused on expanding treatment options with new therapies to further improve patient care within the rheumatology community across the globe."
